help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colclasure, G. C.
Right arrow Articles by Nimberg, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colclasure, G. C.
Right arrow Articles by Nimberg, R. B.

Journal of Clinical Endocrinology & Metabolism, Vol 66, 187-192, Copyright © 1988 by Endocrine Society

ARTICLES

Human serum alpha 2HS-glycoprotein modulates in vitro bone resorption

GC Colclasure, WS Lloyd, M Lamkin, W Gonnerman, RF Troxler, GD Offner, W Burgi, K Schmid and RB Nimberg
Department of Biochemistry, Boston University School of Medicine, Massachusettes 02118.

We previously isolated a family of bone-resorbing proteins from human cancer ascites fluid and established that the three purified bone- resorbing proteins were chemically and immunochemically related to each other and to alpha-2HS glycoprotein (alpha 2HS). After this finding we purified the normal human serum counterpart of these ascites proteins and studied its effects on bone resorption. The bone-resorbing properties of normal human serum alpha 2HS were examined in vitro over a wide dose range. This normal human serum glycoprotein had a biphasic effect on 45Ca2+ release from bone. More specifically, this protein stimulated bone resorption at the lower concentrations tested, with a maximum effect [treated over control ratio of 2.5 +/- 0.30 (+/- SE); P less than 0.01] at 40 micrograms/mL. In contrast, at doses above 40 micrograms/mL, a sharp decline in calcium mobilization occurred, with a return to baseline occurring above 80 micrograms/mL. These results suggest that serum alpha 2HS may participate in the regulation of bone metabolism in vivo.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
H. Chen, P. R. Srinivas, L.-N. Cong, Y. Li, G. Grunberger, and M. J. Quon
{alpha}2-Heremans Schmid Glycoprotein Inhibits Insulin-Stimulated Elk-1 Phosphorylation, But Not Glucose Transport, in Rat Adipose Cells
Endocrinology, October 1, 1998; 139(10): 4147 - 4154.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Nawratil, S. Lenzen, J. Kellermann, H. Haupt, T. Schinke, W. Muller-Esterl, and W. Jahnen-Dechent
Limited Proteolysis of Human alpha 2-HS Glycoprotein/Fetuin. EVIDENCE THAT A CHYMOTRYPTIC ACTIVITY CAN RELEASE THE CONNECTING PEPTIDE
J. Biol. Chem., December 6, 1996; 271(49): 31735 - 31741.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Schinke, C. Amendt, A. Trindl, O. Poschke, W. Muller-Esterl, and W. Jahnen-Dechent
The Serum Protein alpha 2-HS Glycoprotein/Fetuin Inhibits Apatite Formation in Vitro and in Mineralizing Calvaria Cells. A POSSIBLE ROLE IN MINERALIZATION AND CALCIUM HOMEOSTASIS
J. Biol. Chem., August 23, 1996; 271(34): 20789 - 20796.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Demetriou, C. Binkert, B. Sukhu, H. C. Tenenbaum, and J. W. Dennis
Fetuin/alpha 2-HS Glycoprotein Is a Transforming Growth Factor-beta Type II Receptor Mimic and Cytokine Antagonist
J. Biol. Chem., May 31, 1996; 271(22): 12755 - 12761.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society